Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

被引：63

作者：

Gridelli, C ^{[1
]}

Maione, P

Castaldo, V

Rossi, A

机构：

[1] SG Moscati Hosp Via Circumvallaz, Div Med Oncol, I-83100 Avellino, Italy

[2] SG Moscati Hosp Via Circumvallaz, Direz Sanitaria, I-83100 Avellino, Italy

来源：

BRITISH JOURNAL OF CANCER | 2003年 / 89卷 / 10期

关键词：

NSCLC; gefitinib; elderly; poor PS patients;

D O I：

10.1038/sj.bjc.6601387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Elderly and poor performance status advanced non-small-cell lung cancer ( NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib ( Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.

引用

页码：1827 / 1829

页数：3

共 11 条

[1] Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why?
Bunn, PA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 23S - 33S
[2] Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
[3] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
Fossella, FV
DeVore, R
Kerr, RN
Crawford, J
Natale, RR
Dunphy, F
Kalman, L
Miller, V
Lee, JS
Moore, M
Gandara, D
Karp, D
Vokes, E
Kris, M
Kim, Y
Gamza, F
Hammershaimb, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2354 - 2362
[4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
Fukuoka, M
Yano, S
Giaccone, G
Tamura, T
Nakagawa, K
Douillard, JY
Nishiwaki, Y
Vansteenkiste, J
Kudoh, S
Rischin, D
Eek, R
Horai, T
Noda, K
Takata, I
Smit, E
Averbuch, S
Macleod, A
Feyereislova, A
Dong, RP
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
[5] Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
Gridelli, C
Perrone, F
Gallo, C
Cigolari, S
Rossi, A
Piantedosi, F
Barbera, S
Ferraù, F
Piazza, E
Rosetti, F
Clerici, M
Bertetto, O
Robbiati, SF
Frontini, L
Sacco, C
Castiglione, F
Favaretto, A
Novello, S
Migliorino, MR
Gasparini, G
Galetta, D
Iaffaioli, RV
Gebbia, V
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05): : 362 - 372
[6] Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
Gridelli, C
Gallo, C
Shepherd, FA
Illiano, A
Piantedosi, F
Robbiati, SF
Manzione, L
Barbera, S
Frontini, L
Veltri, E
Findlay, B
Cigolari, S
Myers, R
Ianniello, GP
Gebbia, V
Gasparini, G
Fava, S
Hirsh, V
Beziak, A
Seymour, L
Perrone, F
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3025 - 3034
[7] Chemotherapy of non-small cell lung cancer in elderly patients
Gridelli, C
Maione, P
Colantuoni, G
Rossi, A
[J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (16) : 1487 - 1495
[8] Herbst R., 2002, P AN M AM SOC CLIN, V21, P292
[9] MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[10] 2-6

← 1 2 →